NIH Clears First Human Trial of Kratom Compound for Opioid Use Disorder — But Questions Remain

Why it matters

For the first time in history, the FDA has authorized a human clinical trial of a purified kratom compound — a potential turning point for both kratom's scientific legitimacy and its long-term regulatory future.

The big picture

The NIH announced that the FDA allowed an Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound in kratom. This clears the way for an NIH-sponsored Phase I randomized, double-blind, placebo-controlled trial evaluating whether pharmaceutical-grade mitragynine could treat opioid use disorder. Importantly, researchers are studying a purified laboratory compound — not any of the commercial kratom products sold in stores — meaning the results may not apply to what consumers currently purchase.

Key findings

• The FDA authorized the first human Investigational New Drug (IND) application for mitragynine, a kratom alkaloid
• The NIH-sponsored Phase I trial will evaluate safety and tolerability of purified mitragynine as a potential opioid use disorder treatment
• The study is a randomized, double-blind, placebo-controlled trial led by researchers at the University of Florida
• The trial does NOT change current FDA warnings about commercial kratom products, which remain unapproved
• Louisiana's kratom ban and other state-level restrictions are unaffected by the NIH announcement
• The study could take years to complete before conclusions can be drawn on safety or effectiveness

What they say

According to NIH officials, the upcoming study "will be randomized, double-blind, and placebo-controlled" — important scientific safeguards — and focuses on a pharmaceutical-grade compound rather than retail kratom products.

Bottom line

The first federally authorized human trial of a kratom compound is historic — but it does not validate or regulate the commercial kratom products currently on store shelves.